Viral vectors for dendritic cell-based immunotherapy

Trends Immunol. 2001 Feb;22(2):102-7. doi: 10.1016/s1471-4906(00)01813-5.


Transduction of dendritic cells (DCs) by viral vectors genetically engineered to express tumor-associated antigens (TAAs) or cytokines can produce a high level of transgene expression and is an attractive approach for DC-based immunotherapy. Ex vivo transduction allows the control of DC quality, antigen quantity and site of DC reinjection. This review evaluates the viral vectors currently being developed for use in DC-based immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Clinical Trials as Topic
  • Dendritic Cells / transplantation*
  • Genetic Therapy
  • Genetic Vectors / immunology
  • Genetic Vectors / therapeutic use
  • Humans
  • Viral Vaccines / genetics*
  • Viral Vaccines / immunology*
  • Viral Vaccines / therapeutic use


  • Adjuvants, Immunologic
  • Viral Vaccines